Statement: Patients with LVEF equal to 53.5% are eligible for the primary trial.
Primary_evidence: Inclusion Criteria:   female participants, age >/=18 years   advanced, inflammatory or early stage unilateral invasive breast cancer   HER2-positive breast cancer   baseline left ventricular ejection fraction (LVEF) >/=55% Exclusion Criteria:   metastatic disease (Stage IV) or bilateral breast cancer   previous anticancer therapy or radiotherapy for any malignancy   other malignancy, except for carcinoma in situ of the cervix, or basal cell carcinoma   clinically relevant cardiovascular disease   current chronic treatment with corticosteroids of >10mg methylprednisolone or equivalent